People with HIV who have belly fat and are on medication to control the virus who took tesamorelin had higher levels of a growth-related hormone called IGF-1. This finding is from the abstract summary - full study details were not available

Scientific Claim

In virally suppressed, abdominally obese individuals with HIV, tesamorelin treatment is associated with increased insulin-like growth factor 1 levels.

Original Statement

“IGF-1 levels increased, but changes did not correlate with summary regression change score or WC.”

From study:Effects of Tesamorelin on Neurocognitive Impairment in Abdominally Obese Persons with HIV.

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

association

Can only show association/correlation

Assessment Explanation

The study is a randomized trial, which can support association claims. The abstract explicitly states IGF-1 levels increased, and the claim uses 'associated with' which is appropriate given the study's limitations.

Evidence from Studies

Supporting (1)

Effects of Tesamorelin on Neurocognitive Impairment in Abdominally Obese Persons with HIV.

Randomized Controlled Trial

Human

2025 Jun 2

Contradicting (0)

No contradicting evidence found

Source Study

Effects of Tesamorelin on Neurocognitive Impairment in Abdominally Obese Persons with HIV.

Score: 62

DOI: 10.1093/infdis/jiaf012

Similar Assertions

In people with HIV who have belly fat and are on medication to control the virus, changes in IGF-1 levels from tesamorelin treatment did not relate to changes in thinking skills or waist size. This finding is from the abstract summary - full study details were not available

90%

Changes in a growth hormone-related factor didn't match changes in muscle density or size in people with HIV and belly fat taking tesamorelin.

90%

In people with HIV and belly fat who responded to tesamorelin, muscle density changes were linked to belly fat loss but not to changes in a growth-related hormone.

86%

People with HIV who have belly fat and are on medication to control the virus who took tesamorelin had a waist size that was about 2.7 centimeters smaller on average compared to those who didn't, and this difference was statistically significant. This finding is from the abstract summary - full study details were not available

86%

For people with HIV taking tesamorelin, changes in their growth hormone levels didn't match changes in their trunk muscle thickness or size.

85%